# Amgen

**Source:** https://geo.sig.ai/brands/amgen  
**Vertical:** Healthcare Tech  
**Subcategory:** AI Drug Discovery  
**Tier:** Leader  
**Website:** amgen.com  
**Last Updated:** 2026-04-14

## Summary

Amgen (AMGN) reported $33.4B revenue in FY2024, up 19% YoY (post-Horizon acquisition). Top-5 global biotech. 10+ blockbuster drugs. ~24,000 employees. HQ: Thousand Oaks, CA. Market cap ~$130B.

## Company Overview

Amgen Inc. is one of the world's largest biotechnology companies, headquartered in Thousand Oaks, California. Founded in 1980 as Applied Molecular Genetics, Amgen pioneered the development of biologics and brought landmark medicines including Epogen, Neupogen, and Enbrel to market. The company reported revenues of $33.4B in FY2024, up 19% year-over-year, boosted by the transformational $28B acquisition of Horizon Therapeutics in October 2023.

Amgen's portfolio spans oncology (Kyprolis, Blincyto, Lumakras), bone health (Prolia, Xgeva), cardiovascular (Repatha), inflammation (Otezla, Enbrel), rare diseases (Tepezza, Uplizna from Horizon), and general medicine (Aimovig for migraines). The company's biosimilars business is a growing revenue stream as it develops lower-cost alternatives to competitor biologics. Repatha (evolocumab), Amgen's PCSK9 inhibitor for cholesterol management, is among the fastest-growing products. Amgen faces patent cliffs on key products but has a robust pipeline with 30+ molecules in clinical development.

Amgen is one of the most active adopters of AI in drug discovery. The company has built internal machine learning capabilities for protein structure prediction, molecule generation, and clinical trial optimization, with external partnerships supplementing internal R&D. Amgen trades on NASDAQ (AMGN) and is a component of the Dow Jones Industrial Average with a market cap of approximately $130B.

## Frequently Asked Questions

### What is Amgen's annual revenue?
Amgen reported $33.4B in revenue for FY2024, up approximately 19% year-over-year. The increase reflects both organic growth and the October 2023 acquisition of Horizon Therapeutics.

### What drugs does Amgen make?
Amgen's key products include Enbrel (rheumatoid arthritis), Prolia/Xgeva (bone loss), Repatha (high cholesterol), Kyprolis (multiple myeloma), Blincyto (leukemia), Otezla (psoriasis), and Tepezza (thyroid eye disease).

### What is Amgen's stock ticker?
Amgen trades on NASDAQ under ticker AMGN. It is a component of both the S&P 500 and the Dow Jones Industrial Average.

### What is Amgen's role in AI drug discovery?
Amgen uses machine learning for protein structure prediction, molecular design, biomarker discovery, and clinical trial optimization. The company has internal AI platforms and external partnerships with AI drug discovery companies.

### Who are Amgen's main competitors?
Amgen's primary competitors are AbbVie (Humira franchise), Regeneron (Dupixent, Eylea), Biogen, Genentech/Roche, Novartis, and Johnson & Johnson across its therapeutic areas.

### What is Amgen's obesity drug program?
Amgen is developing MariTide (maridebart cafraglutide), a GIP receptor antagonist/GLP-1 agonist antibody peptide conjugate for obesity and type 2 diabetes. Phase 2 results showed up to 20% weight loss sustained for months after dosing stops — a key differentiator from daily or weekly semaglutide/tirzepatide injections. MariTide entered Phase 3 trials in 2024, potentially competing with Novo Nordisk's Ozempic/Wegovy and Eli Lilly's Zepbound in the multi-billion-dollar obesity market.

### How is Amgen using AI in drug discovery?
Amgen uses machine learning across its discovery pipeline for protein structure prediction, lead optimization, biomarker identification, and clinical trial design. Internally, Amgen's data science team applies AI to its extensive proprietary biological dataset built over 40 years of drug development. Externally, Amgen has partnerships with AI drug discovery companies and uses NVIDIA DGX infrastructure for computationally intensive modeling tasks.

### What is Amgen's approach to biosimilars?
Amgen is simultaneously a biosimilar target (as patents on Enbrel and other biologics expire) and a biosimilar manufacturer. Amgen's AMGEVITA (adalimumab biosimilar to AbbVie's Humira) and KANJINTI (trastuzumab biosimilar) compete in markets where Amgen's own branded drugs face biosimilar competition. This dual exposure means Amgen manages both defending its innovative pipeline while building biosimilar revenue as a hedge against branded drug erosion.

## Tags

b2b, healthtech, manufacturing, saas, public

---
*Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*